Xenex Announces StrikeForce Disinfection Service

LightStrike Robot Destroys COVID-19 Virus in 2 Minutes

June 22, 2020

Xenex notes as cities across Texas report a spike in the number of coronavirus cases, businesses and organizations are looking for strategies to combat the virus within their facilities.

Xenex Disinfection Services, the world leader in UV disinfection for healthcare facilities, today announced the launch of StrikeForce, an innovative disinfection service. For the first time, organizations can engage Xenex’s team of environmental disinfection experts on a project basis to utilize Xenex LightStrike Germ-Zapping Robots to kill harmful viruses, bacteria and spores that linger on commonly touched surfaces and pose a risk for disease transmission. StrikeForce is currently limited to engagements in Texas.

“The entire world is thinking about disease transmission as a result of the COVID-19 pandemic. We had numerous requests from businesses who wanted us to bring robots in and disinfect their facilities for them to help ensure that their environment was virus-free. In response to market demand, we developed the StrikeForce service to enable companies to provide their staff and clients peace of mind through innovative disinfection solutions with minimal downtime,” said Irene Hahn, vice president of sales for Xenex.

The LightStrike disinfection robot is proven to destroy Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2), the virus that causes COVID-19, in two minutes. Surfaces contaminated with COVID-19 pose a grave threat to the safety of healthcare workers, patients, frontline responders, military service members, cruise line passengers, hotel guests and citizens everywhere. Deactivating the COVID-19 virus on surfaces is a critical and necessary step to providing a safe environment as businesses reopen and people get back to work. Restaurants, car dealerships, hotels, office buildings, gyms, and many other spaces can benefit immediately from StrikeForce disinfection as the global pandemic demonstrates the need for quick and effective disinfection wherever people work, play, or live.

LightStrike Germ-Zapping Robots use a xenon lamp to generate bursts of high intensity, broad spectrum (200-315nm) ultraviolet (UV) light that’s more intense than sunlight. Different pathogens are susceptible to UVC light at different wavelengths. With broad spectrum germicidal light, Xenex LightStrike robots quickly deactivate viruses, bacteria and spores where they are most vulnerable without damaging materials or equipment.

Xenex is the world leader in UV disinfection for healthcare facilities and its LightStrike robots have been deployed in more than 500 healthcare facilities around the world, including HonorHealth, the Mayo Clinic, MD Anderson Cancer Center, Stanford, and USC. The robots work quickly and do not require warm-up or cool-down time, so facilities are able to disinfect dozens of rooms per day (per robot). Hospitals have published peer-reviewed studies showing significant reductions in Clostridium difficile (C.diff), MRSA, VRE and/or Surgical Site Infection (SSI) rates after integrating Xenex’s infection prevention programs and using LightStrike robots to supplement their environmental disinfection efforts.

Hot this week

Recor Medical Supports European Society of Cardiology’s Hypertension Guidelines

Record Medical notes the new guidelines, "2024 ESC Guidelines for the management of elevated blood pressure and hypertension," have been published online and recommend the consideration of renal denervation (RDN) as a safe and effective treatment option for patients who have uncontrolled resistant hypertension or those that have uncontrolled hypertension with a higher risk of cardiovascular disease, who express a preference to undergo RDN.

ConTIPI Medical Selects EVERSANA to Support U.S. Commercialization of Non-Surgical Medical Device ProVate for Women with Pelvic Organ Prolapse

EVERSANA is a leading provider of global commercial services to the life sciences industry, to support commercialization for the ProVate device in the United States to help women experiencing pelvic organ prolapse.

Boston Scientific Obtains CE Mark for ACURATE Prime Aortic Valve System

The ACURATE Prime aortic valve system is designed with several features to build upon the clinical performance of the ACURATE neo2™ platform including an additional valve size, which expands the treatment range to patients with a larger anatomy.

Noctrix Health Announces New CMS Reimbursement Codes and Payment for Nidra Tonic Motor Activation Therapy for Restless Legs Syndrome

Nidra TOMAC Tonic Motor Activation Therapy, which was authorized for marketing in the United States last year following its designation as a "Breakthrough Device" by the US Food & Drug Administration (FDA), remains the only clinically validated, non-pharmaceutical treatment available for patients with RLS.

Haemonetics Announces Full Market Release for VASCADE MVP® XL Vascular Closure System

Haemonetics notes the VASCADE MVP XL system is now available to U.S. hospitals as the newest addition to Haemonetics' VASCADE® portfolio of vascular closure systems featuring an innovative collapsible disc technology and a proprietary resorbable collagen patch designed to promote rapid hemostasis.